Ensign Peak Advisors
IONS icon

Ensign Peak Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Ensign Peak Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$723K Sell
9,120
-36,884
-80% -$2.78M ﹤0.01% 895
2026
Q1 		$3.45M Sell
46,004
-7,660
-14% -$605K 0.01% 607
2025
Q4 		$4.25M Buy
53,664
+26,069
+94% +$1.96M 0.01% 551
2025
Q3 		$1.81M Sell
27,595
-25,725
-48% -$1.26M ﹤0.01% 830
2025
Q2 		$2.11M Sell
53,320
-1,780
-3% -$58.3K ﹤0.01% 880
2025
Q1 		$1.66M Buy
55,100
+1,780
+3% +$58.3K ﹤0.01% 988
2024
Q4 		$1.86M Sell
53,320
-16,560
-24% -$619K ﹤0.01% 969
2024
Q3 		$2.8M Buy
69,880
+1,610
+2% +$74.9K ﹤0.01% 813
2024
Q2 		$3.25M Buy
68,270
+14,950
+28% +$613K 0.01% 750
2024
Q1 		$2.31M Buy
53,320
+7,010
+15% +$334K ﹤0.01% 866
2023
Q4 		$2.34M Hold
46,310
– – ﹤0.01% 849
2023
Q3 		$2.1M Hold
46,310
– – ﹤0.01% 826
2023
Q2 		$1.9M Hold
46,310
– – ﹤0.01% 899
2023
Q1 		$1.66M Sell
46,310
-8,581
-16% -$322K ﹤0.01% 923
2022
Q4 		$2.07M Buy
54,891
+22,576
+70% +$950K ﹤0.01% 798
2022
Q3 		$1.43M Buy
32,315
+7,445
+30% +$314K ﹤0.01% 911
2022
Q2 		$921K Hold
24,870
– – ﹤0.01% 1151
2022
Q1 		$921K Sell
24,870
-3,460
-12% -$113K ﹤0.01% 1254
2021
Q4 		$862K Buy
+28,330
New +$892K ﹤0.01% 1366
2021
Q1 		– Sell
-4,882
Closed -$276K – 1858
2020
Q4 		$276K Sell
4,882
-5,198
-52% -$259K ﹤0.01% 1687
2020
Q3 		$478K Buy
+10,080
New +$560K ﹤0.01% 1538
2020
Q1 		– Sell
-5,574
Closed -$337K – 1660
2019
Q4 		$337K Buy
+5,574
New +$332K ﹤0.01% 1577

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Ensign Peak Advisors's IONS Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Ionis Pharmaceuticals (IONS) stake by 80% in Q2 2026, selling an estimated $2.78M and leaving 9,120 shares worth $723K. The position accounts for ﹤0.01% of the portfolio, ranked #895.

Ensign Peak Advisors first reported a position in IONS in Q4 2019 and has held it in 22 quarters since. The position peaked at $4.25M in Q4 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Ensign Peak Advisors held 9,120 shares of Ionis Pharmaceuticals worth $723K as of Q2 2026.
  • Ensign Peak Advisors sold 36,884 Ionis Pharmaceuticals shares in Q2 2026, an estimated $2.78M.
  • Ionis Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #895 holding.
  • Ensign Peak Advisors first reported a position in Ionis Pharmaceuticals in Q4 2019 and has held it in 22 quarters since.
  • Ensign Peak Advisors's Ionis Pharmaceuticals position peaked at $4.25M in Q4 2025.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.